This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/026293-2021</u>

Contract

Advance Purchase Agreement

Business Energy and Industrial Strategy

F03: Contract award notice Notice identifier: 2021/S 000-026293 Procurement identifier (OCID): ocds-h6vhtk-02ee22 Published 20 October 2021, 4:33pm

Section I: Contracting authority

I.1) Name and addresses

Business Energy and Industrial Strategy

1 Victoria Street

London

SW1H0ET

Email

VTFContracts@beis.gov.uk

Country

United Kingdom

NUTS code

UKI32 - Westminster

Internet address(es)

Main address

https://www.gov.uk/government/organisations/department-for-business-energy-andindustrial-strategy

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

General public services

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Advance Purchase Agreement

Reference number

2611/09/2020

II.1.2) Main CPV code

• 33651600 - Vaccines

II.1.3) Type of contract

Supplies

II.1.4) Short description

Procurement of the Covid-19 Adjuvanted Pandemic Vaccine.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £1

II.2) Description

II.2.3) Place of performance

NUTS codes

• UK - United Kingdom

II.2.4) Description of the procurement

Procurement of the Covid-19 Adjuvanted Pandemic Vaccine.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.14) Additional information

Contract value is being withheld due to commercial sensitivity (PCR 2015 Reg 50(6)(b) and (c) and FOIA 2000 Section 43). Publication may enable competitors to calculate cost per dose. This will commercially prejudice:

(i) the supplier in its negotiations with other national governments; and

(ii) the contracting authority in negotiations with other vaccine vendors. It may also impact fair competition between vaccine vendors.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The services can be provided only by a particular economic operator for the following reason:
 - absence of competition for technical reasons
- Additional deliveries by the original supplier

Explanation:

The award of the contract to Aventis Pharma and GSK is strictly necessary due to absence of competition for technical reasons. Regulation 32 (b)(ii).

Furthermore, this Advance Purchase Agreement is the execution of the previous Capacity Reservation Agreement (Please see linked notice)

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: 2020/S 227-560526

Section V. Award of contract

Contract No

2611/09/2020

Title

Advance Purchase Agreement

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

20 September 2021

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: Yes

V.2.3) Name and address of the contractor

Aventis Pharma Ltd

Thames Valley Park Drive, Reading

Berkshire

RG6 1PT

Country

United Kingdom

NUTS code

• UK - United Kingdom

The contractor is an SME

No

V.2.3) Name and address of the contractor

GlaxoSmithKline Biologicals S.A

Rue de l'Institut 89

Rixensart

B-1330

Country

Belgium

NUTS code

• BE - Belgium

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £1

Total value of the contract/lot: £1

Section VI. Complementary information

VI.3) Additional information

Additional information: contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market. Also, given significant competition to bring to the market a successful vaccine, provision of the contract term is valuable information to competitors that may impact negotiations/future competition.

VI.4) Procedures for review

VI.4.1) Review body

Department of Business, Energy and Industrial Strategy

1 Victoria Street, Westminister

London

SW1H 0ET

Country

United Kingdom